Feasibility study of FOLFIRINOX as first-line chemotherapy for metastatic pancreatic cancer (KOBE FOLFIRINOX study)

被引：0
|
作者：
Hatachi, Yukimasa [1 ]
Satake, Hironaga [1 ]
Kotake, Takeshi [1 ]
Ogata, Takatsugu [1 ]
Okita, Yoshihiro [2 ]
Yasui, Hisateru [1 ]
Tsuji, Akihito [2 ]
机构：
[1] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Hyogo, Japan
[2] Kagawa Univ Hosp, Dept Clin Oncol, Miki, Kagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-104
引用
收藏
页数：1
相关论文
共 50 条
  • [1] NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
    Nichetti, Federico
    Rota, Simone
    Ambrosini, Paolo
    Pircher, Chiara
    Gusmaroli, Eleonora
    Busset, Michele Droz Dit
    Pusceddu, Sara
    Sposito, Carlo
    Coppa, Jorgelina
    Morano, Federica
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    Mariani, Luigi
    Mazzaferro, Vincenzo
    de Braud, Filippo
    Niger, Monica
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [2] The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer
    Wang, Zhi-Qiang
    Zhang, Fei
    Deng, Ting
    Zhang, Le
    Feng, Fen
    Wang, Feng-Hua
    Wang, Wei
    Wang, De-Shen
    Luo, Hui-Yan
    Xu, Rui-Hua
    Ba, Yi
    Li, Yu-Hong
    CANCER COMMUNICATIONS, 2019, 39
  • [3] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer
    Attard, C. L.
    Brown, S.
    Alloul, K.
    Moore, M. J.
    CURRENT ONCOLOGY, 2014, 21 (01) : E41 - E51
  • [4] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [5] Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine.
    Arlen, Aimee Ginsburg
    Cartwright, Thomas H.
    Wilfong, Lalan S.
    Hoverman, J. Russell
    Nelson, Greg C.
    Turnwald, Brian
    Beveridge, Roy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.
    Attard, Cheryl L.
    Brown, Stephen
    Alloul, Karine
    Moore, Malcolm J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [7] Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer A Retrospective Multicentric Analysis
    Caron, Benedicte
    Reimund, Jean-Marie
    Ben Abdelghani, Meher
    Sondag, Daniel
    Noirclerc, Monique
    Duclos, Bernard
    Kurtz, Jean-Emmanuel
    Nguimpi-Tambou, Marlene
    PANCREAS, 2021, 50 (06) : 803 - 806
  • [8] FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer
    Giuliani, Jacopo
    Bonetti, Andrea
    PANCREATOLOGY, 2019, 19 (02) : 325 - 330
  • [9] Updated use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine
    Cartwright, Thomas H.
    Arlen, Aimee Ginsburg
    Wilfong, Lalan S.
    Harrell, Robyn K.
    Hoverman, J. Russell
    Beveridge, Roy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study
    Vienot, Angelique
    Chevalier, Hortense
    Bolognini, Clement
    Gherga, Elisabeta
    Klajer, Elodie
    Meurisse, Aurelia
    Jary, Marine
    Kim, Stefano
    d'Engremont, Christelle
    Nguyen, Thierry
    Calcagno, Fabien
    Almotlak, Hamadi
    Fein, Francine
    Nasri, Meher
    Abdeljaoued, Syrine
    Turpin, Anthony
    Borg, Christophe
    Vernerey, Dewi
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (03) : 332 - 346
12345